Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant Human Coagulation Factor VIII (Wuhan Zhong Yuan Rui De)
- Development stage
- Unknown
- Lead developer
- Wuhan Zhong Yuan Rui De Biological Products
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant Human Coagulation Factor VIII for Injection is a recombinant protein biologic developed by Wuhan Zhong Yuan Rui De Biological Products (a subsidiary of Chengdu Rongsheng Pharmaceutical and Tiantan Bio) for the treatment of hemophilia A. As a replacement therapy, the drug provides the deficient Coagulation Factor VIII protein necessary for the blood clotting cascade. By restoring functional levels of Factor VIII, it corrects the bleeding tendency and allows for the formation of stable fibrin clots in patients with hemophilia A. The product is administered via intravenous injection and has received regulatory approval in China.
- Other names
- Recombinant Human Coagulation Factor VIII for Injectionrecombinant FVIII注射用重组人凝血因子VIII
02
Targets
Phosphatidylserine-enriched platelet membraneBB-031 (Von Willebrand factor)Coagulation Factor IXaF10 (Factor Xa)
Beyond the preview
Go deeper on Recombinant Human Coagulation Factor VIII (Wuhan Zhong Yuan Rui De).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant Human Coagulation Factor VIII (Wuhan Zhong Yuan Rui De).